CO6410283A2 - Métodos para administrar (4ar,10ar)-1-n-propil-1,2,3,4,4a,5,10,10a-octahidro-benzo[g]quinolin-6,7-diol y compuestos relacionados a través de la mucosa oral, la mucosa nasal o la piel, y sus compoisiciones farmacéuticas - Google Patents

Métodos para administrar (4ar,10ar)-1-n-propil-1,2,3,4,4a,5,10,10a-octahidro-benzo[g]quinolin-6,7-diol y compuestos relacionados a través de la mucosa oral, la mucosa nasal o la piel, y sus compoisiciones farmacéuticas

Info

Publication number
CO6410283A2
CO6410283A2 CO11106894A CO11106894A CO6410283A2 CO 6410283 A2 CO6410283 A2 CO 6410283A2 CO 11106894 A CO11106894 A CO 11106894A CO 11106894 A CO11106894 A CO 11106894A CO 6410283 A2 CO6410283 A2 CO 6410283A2
Authority
CO
Colombia
Prior art keywords
quinolin
benzo
methods
pharmaceutical compositions
diol
Prior art date
Application number
CO11106894A
Other languages
English (en)
Inventor
Hakan Wikstroom
Morten Jorgensen
Lars Torup
Ask Puschl
Thomas Nikolaj Sager
Jennifer Larsen
Niels Mork
Benny Bang-Andersen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42102075&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6410283(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of CO6410283A2 publication Critical patent/CO6410283A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen composiciones farmacéuticas y métodos para la administración de (4aR, 10aR)-1-n-propil-1,2,3,4,4a,5,10,10a-octahidro-benzo[g] quinolin-6,7-diol o una sal farmacéuticamente aceptable del mismo y compuestos relacionados para el tratamiento de trastornos neurológicos tales como la enfermedad de Parkinson y el síndrome de las piernas inquietas.
CO11106894A 2009-02-27 2011-08-23 Métodos para administrar (4ar,10ar)-1-n-propil-1,2,3,4,4a,5,10,10a-octahidro-benzo[g]quinolin-6,7-diol y compuestos relacionados a través de la mucosa oral, la mucosa nasal o la piel, y sus compoisiciones farmacéuticas CO6410283A2 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US15594209P 2009-02-27 2009-02-27
US15593309P 2009-02-27 2009-02-27
US15595709P 2009-02-27 2009-02-27
DKPA200900282 2009-02-27
DKPA200900279 2009-02-27
DKPA200900274 2009-02-27

Publications (1)

Publication Number Publication Date
CO6410283A2 true CO6410283A2 (es) 2012-03-30

Family

ID=42102075

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11106894A CO6410283A2 (es) 2009-02-27 2011-08-23 Métodos para administrar (4ar,10ar)-1-n-propil-1,2,3,4,4a,5,10,10a-octahidro-benzo[g]quinolin-6,7-diol y compuestos relacionados a través de la mucosa oral, la mucosa nasal o la piel, y sus compoisiciones farmacéuticas

Country Status (17)

Country Link
US (1) US20120077836A1 (es)
EP (1) EP2400955A1 (es)
JP (1) JP2012519156A (es)
KR (1) KR20110138213A (es)
CN (1) CN102333524A (es)
AR (1) AR075626A1 (es)
AU (1) AU2010217058A1 (es)
BR (1) BRPI1006953A2 (es)
CA (1) CA2751321A1 (es)
CL (1) CL2011002100A1 (es)
CO (1) CO6410283A2 (es)
EA (1) EA201171087A1 (es)
IL (1) IL213501A0 (es)
MX (1) MX2011008627A (es)
SG (1) SG174164A1 (es)
TW (1) TW201035054A (es)
WO (1) WO2010097091A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160030961A (ko) * 2013-07-17 2016-03-21 다우 글로벌 테크놀로지스 엘엘씨 메틸셀룰로오스를 포함하는 점막에 적용하기 위한 조성물
TWI816716B (zh) 2017-11-24 2023-10-01 丹麥商Ｈ 朗德貝克公司 用於治療帕金森病之新兒茶酚胺前驅藥
US11111263B2 (en) * 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
CN113727974A (zh) * 2019-05-21 2021-11-30 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303684B1 (it) * 1998-10-30 2001-02-23 Chiesi Farma Spa Formulazioni di apomorfina in soluzione stabili nel tempo.
US6765001B2 (en) * 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
TWI404702B (zh) * 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥

Also Published As

Publication number Publication date
US20120077836A1 (en) 2012-03-29
MX2011008627A (es) 2011-09-06
AU2010217058A1 (en) 2011-09-08
TW201035054A (en) 2010-10-01
IL213501A0 (en) 2011-07-31
CL2011002100A1 (es) 2012-06-22
EA201171087A1 (ru) 2012-02-28
AR075626A1 (es) 2011-04-20
CA2751321A1 (en) 2010-09-02
WO2010097091A1 (en) 2010-09-02
BRPI1006953A2 (pt) 2016-04-26
KR20110138213A (ko) 2011-12-26
JP2012519156A (ja) 2012-08-23
CN102333524A (zh) 2012-01-25
SG174164A1 (en) 2011-10-28
EP2400955A1 (en) 2012-01-04

Similar Documents

Publication Publication Date Title
CO6410283A2 (es) Métodos para administrar (4ar,10ar)-1-n-propil-1,2,3,4,4a,5,10,10a-octahidro-benzo[g]quinolin-6,7-diol y compuestos relacionados a través de la mucosa oral, la mucosa nasal o la piel, y sus compoisiciones farmacéuticas
EA201200002A1 (ru) Производные индоламида и родственные соединения для использования при лечении нейродегенеративных заболеваний
DOP2011000343A (es) Derivados de piridina tieno [2,3-b] como inhibidores de replicacion viral
ECSP12012171A (es) Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos
CO6361928A2 (es) Modulares de aril metil benzoquinazolinona alostericos positivos del receptor m1
BR112014003225A2 (pt) profármacos de treprostinil ligados a veículo
NZ598021A (en) Prodrugs comprising an insulin linker conjugate
UY32629A (es) Compuestos antivirales, composiciones y uso para la manufactura de un medicamento para el tratamiento de trastornos asociados con hepatitis c.
MX348983B (es) Profarmacos que comprenden un conjugado de conector de exendina.
UY31405A1 (es) "piperidino-dihidrotienopirimidas sustituidas"
CU24037B1 (es) Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido
EA201171088A1 (ru) Лечение дискинезии при различных расстройствах
CR20120084A (es) Composiciones farmacéuticas para el tratamiento del cáncer y otras enfermedades o trastornos
EA201400067A1 (ru) Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента
DOP2013000314A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
CR11734A (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
DK2244703T3 (da) Lægemiddel og fremstillingen og anvendelse deraf i behandlingen af smertefulde neuropatier
UY28590A1 (es) Procedimiento para la preparación de nuevas sales de tiotropio, nuevas sales de tiotropio como tales, así como las formulaciones medicamentosas que las contienen.
AR088845A1 (es) Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel
CO6331429A2 (es) Derivados de 5-(4-metanosulfonil-fenil)-tiazol para el tratamiento de enfermedades inflamatorias agudas y cronicas
AR074246A1 (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno
EA201101708A1 (ru) Фармацевтическая композиция для лечения желудочных расстройств
EA200900174A8 (ru) Фармацевтическая композиция для лечения желудочных расстройств
ECSP12011632A (es) Profármacos que comprenden un conjugado de insulina-conector
TH132242B (th) องค์ประกอบทางเภสัชกรรมที่ประกอบด้วยไฮโดรมอร์โฟนและนาล็อกโซน (Pharmaceutical compositions comprising hydromorphone and naloxone)

Legal Events

Date Code Title Description
FC Application refused